Coherus Biosciences | CHRS - Sales Revenues


Coherus Biosciences reported $12.75M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 392.91M 8.41M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Fujifilm JPY 927.25B 69.9B Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
Merck USD 16.29B 110M Mar/2026
Myriad Genetics USD 200.4M 9.4M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026
Zoetis USD 2.3B 100M Mar/2026